285 related articles for article (PubMed ID: 23361102)
1. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
Ulvestad M; Skottheim IB; Jakobsen GS; Bremer S; Molden E; Asberg A; Hjelmesæth J; Andersson TB; Sandbu R; Christensen H
Clin Pharmacol Ther; 2013 Mar; 93(3):275-82. PubMed ID: 23361102
[TBL] [Abstract][Full Text] [Related]
2. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
Lee YJ; Lee MG; Lim LA; Jang SB; Chung JY
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):36-45. PubMed ID: 20040338
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD
Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503
[TBL] [Abstract][Full Text] [Related]
5. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Niemi M; Kivistö KT; Diczfalusy U; Bodin K; Bertilsson L; Fromm MF; Eichelbaum M
Pharmacogenet Genomics; 2006 Aug; 16(8):565-8. PubMed ID: 16847425
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
[TBL] [Abstract][Full Text] [Related]
7. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
[TBL] [Abstract][Full Text] [Related]
8. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
9. Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil.
Srinivas NR
Eur J Clin Pharmacol; 2008 Nov; 64(11):1135-6. PubMed ID: 18661126
[No Abstract] [Full Text] [Related]
10. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
11. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.
Marusic S; Lisicic A; Horvatic I; Bacic-Vrca V; Bozina N
Int J Clin Pharm; 2012 Dec; 34(6):825-7. PubMed ID: 23076661
[TBL] [Abstract][Full Text] [Related]
13. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
Lau YY; Huang Y; Frassetto L; Benet LZ
Clin Pharmacol Ther; 2007 Feb; 81(2):194-204. PubMed ID: 17192770
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
[TBL] [Abstract][Full Text] [Related]
15. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
[TBL] [Abstract][Full Text] [Related]
16. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Higgins JW; Bao JQ; Ke AB; Manro JR; Fallon JK; Smith PC; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2014 Jan; 42(1):182-92. PubMed ID: 24194513
[TBL] [Abstract][Full Text] [Related]
17. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Romaine SP; Bailey KM; Hall AS; Balmforth AJ
Pharmacogenomics J; 2010 Feb; 10(1):1-11. PubMed ID: 19884908
[TBL] [Abstract][Full Text] [Related]
18. Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Srinivas NR
J Clin Pharmacol; 2009 Dec; 49(12):1492-3. PubMed ID: 19955497
[No Abstract] [Full Text] [Related]
19. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
[TBL] [Abstract][Full Text] [Related]
20. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.
Hermann M; Bogsrud MP; Molden E; Asberg A; Mohebi BU; Ose L; Retterstøl K
Clin Pharmacol Ther; 2006 Jun; 79(6):532-9. PubMed ID: 16765141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]